Rachel Zentner, MD
Psychiatry · Hastings, NENPI 1669813549
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 473 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 31.4% of the total. Reporting peaked in 2022 at $1,264 and has fallen 66.8% since, to $420 in 2025.
Across 473 payments — averaging $11.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$886
- Alkermes, Inc.$623
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$550
- Otsuka America Pharmaceutical, Inc.$519
- Teva Pharmaceuticals USA, Inc.$350
- plus $946 from 17 others
What the payments were for
- Food & beverage$5,60699%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 156 | $1,772 |
| Johnson & Johnson | 98 | $886 |
| Alkermes, Inc. | 70 | $623 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $550 |
| Otsuka America Pharmaceutical, Inc. | 36 | $519 |
| Teva Pharmaceuticals USA, Inc. | 26 | $350 |
| Sunovion Pharmaceuticals Inc. | 17 | $220 |
| Neurocrine Biosciences, Inc. | 10 | $167 |
| Ironshore Pharmaceuticals Inc. | 7 | $128 |
| Lundbeck LLC | 6 | $87 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Indivior Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Corium, LLC | 2 | $22 |
| Gilead | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
How this compares
$5,646 in reported general payments places this provider in the 85th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 75 | $497,420 |
| IngrezzaValbenazine Tosylate | 40 | $342,405 |
| VraylarCariprazine Hcl | 159 | $209,428 |
| Invega SustennaPaliperidone Palmitate | 58 | $193,485 |
| Abilify AsimtufiiAripiprazole | 14 | $78,399 |
| RexultiBrexpiprazole | 58 | $71,146 |
| Risperdal ConstaRisperidone Microspheres | 49 | $61,442 |
| CaplytaLumateperone Tosylate | 35 | $58,108 |
| TrintellixVortioxetine Hydrobromide | 89 | $44,533 |
| AuvelityDextromethorphan Hbr/Bupropion | 34 | $44,016 |
| Vilazodone Hcl | 231 | $23,210 |
| Paliperidone ErPaliperidone | 50 | $15,964 |
| Bupropion XlBupropion Hcl | 298 | $14,844 |
| BelsomraSuvorexant | 28 | $13,916 |
| DayvigoLemborexant | 37 | $12,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $350 | $497,42075 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $167 | $342,40540 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $886 | $254,927107 claims |
| AbbVieVraylar, Fetzima | $1,772 | $216,492173 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $519 | $149,54572 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $550 | $58,10835 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $32 | $53,280113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Hastings
- Kavir SaxenaHastings$4K
- Vithyalakshmi SelvarajOmaha$1.2M
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Navdeep SoodGrand Island$51K
- Walter DuffyLincoln$46K
- Dianna ClyneLincoln$19K
- Jeffrey CoffmanLincoln$18K
- Syed SattarOmaha$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.